Objectives: The involvement of skeletal muscle mitochondrial uncoupling protein-3 (UCP3) in the control of energy expenditure in skeletal muscle and at the whole-body level is still a matter of debate. We previously reported that UCP3 downregulation is linked to an enhanced mitochondrial energy metabolism in rat skeletal muscle as a result of acute capsiate treatment. Here, we aimed at investigating noninvasively the effects of chronic capsiate ingestion on metabolic changes occurring in exercising gastrocnemius muscle and at the whole-body level. Methods: We used an original experimental setup allowing a complete noninvasive investigation of gastrocnemius muscle function in situ using 31-phosphorus magnetic resonance spectroscopy. Whole-body fat composition was determined using magnetic resonance imaging and UCP3 gene expression was measured by quantitative real-time RT-PCR analysis. Results: We found that a 14-day daily administration of capsiate (100 mg kg À1 body weight) reduced UCP3 gene expression and increased phosphocreatine level at baseline and during the stimulation period in gastrocnemius muscle. During muscle stimulation, pH i showed a larger alkalosis in the capsiate group suggesting a lower glycolysis and a compensatory higher aerobic contribution to ATP production. Although the capsiate-treated rats were hyperphagic as compared to control animals, they showed a lower weight gain coupled to a decreased abdominal fat content. Conclusion: Overall, our data indicated that capsiate administration contributes to the enhancement of aerobic ATP production and the reduction of body fat content coupled to a UCP3 gene downregulation.
Introduction
Our understanding of mechanisms controlling muscle energy consumption either at rest or during exercise is still a matter of interest. Given that skeletal muscle accounts for almost half of the total body mass, muscle energy expenditure has received a particular attention regarding the possible mechanisms of energy dissipation through uncoupling processes. The third member of the uncoupling protein family, uncoupling protein-3 (UCP3), is a mitochondrial inner membrane protein which is highly and preferentially expressed in skeletal muscle. 1 Based on its closed sequence homology with uncoupling protein-1 (UCP1), a protein that uncouples respiration from ATP production in brown adipose tissue thereby promoting heat production in response to cold or overfeeding, it has been suggested that UCP3 could be involved in the control of muscle energy expenditure. 2 Although the molecular basis of this mechanism is unclear, UCP3 could be considered as a potential therapeutic target of obesity considering its involvement in metabolic efficiency. To date, there is no consensus regarding the exact function of UCP3. Several studies have suggested that UCP3 could uncouple mitochondrial respiration when activated by superoxide or reactive oxygen species derivatives thereby reducing the corresponding production of mitochondrial reactive oxygen species and the resulting cellular damage. 3 It has been also proposed that UCP3 could behave as a mitochondrial fatty acid anion transporter thereby mitigating lipotoxicity. 4 Overall, the metabolic modifications associated with UCP3 expression and more particularly muscle energy consumption and fat metabolism warrant further investigations. Accordingly, investigations of phenotypic changes have been conducted in mice disrupted for the UCP3 gene but the corresponding results have not been conclusive regarding the role of UCP3 in energy expenditure and in the metabolic control of body weight. Alternatively, metabolic changes resulting from chemically induced alteration in UCP3 gene expression have been investigated. In that respect, we have recently shown that a single oral administration of capsiate, a natural and edible compound, significantly downregulated UCP3 gene expression in rat skeletal muscle while the rate of mitochondrial ATP production was increased both at rest and during a standardized stimulation protocol. 5 The capsiate-mediated UCP3 downregulation coupled to an increased rate of mitochondrial ATP production was not associated to any improvement in muscle-force-generating capacity. This suggests that the increased rate of aerobic ATP production could compensate additional noncontractile ATP-consuming process(es) and that capsiate could ultimately promote energy consumption and could be considered as an attractive compound for the treatment of obesity. Capsiate is a chemical analog of capsaicin and belongs to the capsinoid family. Although hot pepper or capsaicin may be used in a diet therapy against obesity, their usage as a food additive or as a drug is limited by its strong pungency in humans. Conversely, capsiate is a nonpungent compound extracted from a sweet pepper named 'CH-19 sweet' wherein it is highly concentrated. Infrared thermography and indirect calorimetry experiments have shown that a single intake of 'CH-19 sweet' fruit increases body temperature and basal oxygen consumption in resting humans, hence suggesting that CH-19 sweet promotes thermogenesis and energy consumption. 6 The aim of this study was to determine whether chronic administration of capsiate affects whole-body fat composition and skeletal muscle energy metabolism at rest and during exercise. We used an original experimental setup allowing muscle function to be assessed strictly noninvasively in situ using magnetic resonance (MR) techniques and mechanical performance measurements. 7 The corresponding results were analyzed together with measurements of wholebody fat composition using magnetic resonance imaging (MRI) and changes in UCP3 gene expression. Investigation of muscle function Animal preparation. The right lower hindlimb was shaved and electrode cream for electromyogram measurements was applied at the knee and heel levels to optimize electrical stimulation. Anesthetized animals were placed supine in a home-built cradle especially designed for the strictly noninvasive functional investigation of the right gastrocnemius muscle. 7 This cradle integrates a hydraulic ergometer and two rod-shaped transcutaneous electrodes (located above the knee and under the heel, respectively) connected to an electrical stimulator (Stimulator I series; Hugo Sachs Elektronik, Harvard Apparatus). The foot was positioned on the ergometer pedal and the hindlimb was immobilized in the cradle so that the lower hindlimb was centered inside a 30-mm-diameter 1 H Helmholtz imaging coil and the belly of the gastrocnemius muscle was located above an elliptic (10 Â 16 mm) 31 P-MRS surface coil. The pedal position was adjusted to modify the angle between the foot and the lower hindlimb so that the gastrocnemius muscle was passively stretched at rest and produced a maximum isometric twitch tension in response to supramaximal square-wave pulses (6-8 mA, 1 ms duration).
Materials and methods
Stimulation protocol and force measurement. The 5.7 min stimulation protocol consisted in electrical stimulations delivered at a frequency of 3.3 Hz using square-wave pulses (6-8 mA, 1 ms duration) and triggering repeated isometric contractions. Electrical signal coming out from the pressure transducer was amplified (ref. 13-4515-50 ; Gould, Cleveland, OH, USA), converted to a digital signal and processed on a personal computer using ATS software (Sysma, Aix-enProvence, France). Isometric force production was calculated for each 14.25 s period of stimulation by integrating isometric tension (N) with respect to time (s).
MR spectroscopy and data processing.
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P-MR spectra (30 ms rectangular pulse; 16 accumulations; 1.8 s repetition time; 8 kHz spectral width, 512 data points) from the gastrocnemius muscle region were continuously acquired in 28.5 s blocks throughout the experimental protocol, that is, 5.7 min of rest, 5.7 min of stimulation and 16.6 min of recovery. MR data acquisition was gated to muscle stimulation to reduce motion artifacts due to contraction. Relative concentrations of phosphocreatine (PCr) and ATP were obtained by a timedomain fitting routine using the AMARES-MRUI Fortran code 10 and appropriate prior knowledge of the ATP multiplets.
Signal areas were corrected for magnetic saturation effects using fully relaxed spectra collected at rest with a repetition time of 20 s. Absolute concentrations of phosphorylated compounds were expressed relative to ATP concentration measured using HPLC from extracts of freeze-clamped resting gastrocnemius muscle from both groups. ).
12
Abdominal fat volume measurement Magnetic resonance imaging acquisitions were performed using a whole-body imaging coil (PRK 200 RES 200; Brüker). Noncontiguous axial imaging slices (3 mm thickness, 5 mm spaced) were selected across the entire body length excluding the tail. RARE 3D images of these slices (6.714 ms echo time; 94.52 ms effective echo time; 400 ms repetition time, 10 Â 10 cm field of view, 256 Â 256 matrix size) were recorded at rest. To reduce motion artifacts, image acquisition was triggered to animal respiration using an air-filled balloon positioned under the abdomen and connected to a pressure transducer placed outside the magnet. MRI data were processed using proprietary software developed on IDL (Interactive Data Language; Research System Inc., Boulder, CO, USA). Absolute quantification of the fat depots was performed from the base of the kidney to the base of the tail.
Quantitative real-time RT-PCR analysis Gastrocnemius muscle was dissected and immediately frozen in liquid nitrogen and then homogenized. Total RNA was extracted with TRIzol reagent (Invitrogen, Carlsbad, CA, USA) according to the manufacturer's protocol. RNA was then treated with 1 U DNase I (Promega, San Luis Obispo, CA, USA) to remove genomic DNA and reverse-transcribed to cDNA using the Superscript III first-strand RT-PCR system kit (Invitrogen). Briefly, 4 mg of RNA was added with 50 ng of random hexamer primers, 1 mM dNTP mix, 40 U RNaseOUT and 1 U Superscript retrotranscriptase. Two units of RNase H were added at the end of the reactions. Real-time PCR was carried out using an ABI prism 7000 cycler (Applied Biosystem, Framingham, MA, USA) with SYBR Green as the fluorescent dye (Bio-Rad, Hercules, CA, USA), a 1/10 vol of the cDNA preparation as template and 500 nM for each primer. 5 The cycle used for the PCR reaction was as follows: 
Statistics
For variables evolving with time during the stimulation period (force production, metabolite concentration and pH i ), the effect of capsiate on the overall time course was tested with one-way repeated-measures analyses of variance (ANOVAs; JMP software; SAS Institute Inc., Cary, NC, USA) and, when appropriate, with post hoc testing (Fisher's test) to localize significant differences at each time point. Other variables were compared using Student's t-test. Values are means ± s.e.m. P-values of less than 0.05 were considered significant.
Results

Measurements of body weight gain and cumulative food intake
At the start of the experiment, average body weight in the capsiate and the control groups was similar (271±3 g vs 272 ± 2 g, respectively). Over the course of the 14-day treatment period, body weight increased in both groups but the body weight gain in the capsiate group was three times lower than in the control group (2.4 ± 0.97 vs 7.2 ± 1.3 g, respectively; Figure 1 ). During the same period, food consumption was 45% higher in treated animals as compared to the control group (Table 1) . The calculated feed efficiency (weight gain (g)/food intake (g)) was 77% lower in the capsiate group indicating a lower body weight gain for a given amount of food consumed (Table 1) .
Longitudinal MRI quantification of abdominal fat volume
Abdominal fat volume was measured in vivo from serial MRI slices acquired before and at the end of the 14-day treatment period in the same animals receiving either the vehicle or the capsiate solution. The surface of intra-abdominal fat was quantified from each slice as illustrated in Figure 2 . MRI measurements showed that the abdominal fat volume was increased in the control group whereas it was decreased in the rats treated with capsiate ( þ 200.3 ± 68.2 vs À234.1 ± 99.2 mm In both groups, pH i fell rapidly in the first part of the stimulation protocol and reached a steady state after the third minute of stimulation. The steady-state value was significantly higher (less acidic) in the capsiate group when compared to controls. At the end of the stimulation period, pHi was 6.30 ± 0.02 and 6.41 ± 0.02 in the control and capsiate groups, respectively.
[ATP] slightly decreased during the stimulation period under both conditions. At the end of the stimulation period, it was 3.1 ± 0.2 and 3.7 ± 0.4 mM in control and capsiatetreated animals, respectively. 
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For both groups, [ADP] time courses were strongly similar with a rapid increase in the early stage of the stimulation period followed by a decrease after 1 min of stimulation (Figure 4d) .
The capsiate treatment did not affect the maximal rate of oxidative ATP synthesis and the initial rate of PCr recovery during the post-stimulation period (Table 2) .
Mechanical measurements
Capsiate treatment did not affect the overall time course of isometric force (Figure 4e) . In both groups, isometric force transiently increased in the early stage of the stimulation period and reached a maximal value. Afterward, isometric force production strongly decreased throughout the stimulation period in control and capsiate groups as a sign of a marked muscular fatigue development. The extent of force reduction throughout the stimulation period was 69.1 ± 4.0 and 71.6±4.6% of the initial value in control and capsiate groups, respectively.
Quantitative measurements of UCP3 gene expression
A real-time quantitative RT-PCR was performed to quantify UCP3 gene expression in gastrocnemius muscle following the 14-day treatment with vehicle or capsiate solution. As illustrated in Figure 5 , capsiate administration reduced more than twofold UCP3 mRNA expression level as compared to control conditions.
Discussion
We demonstrated in the present study that UCP3 gene expression and muscle energy metabolism in gastrocnemius muscle were modified as a result of capsiate administration. In addition, at the whole-body level, abdominal fat volume and body weight gain were reduced whereas food consumption increased.
A major finding of the present study is that capsiate administered daily during a 2-week period significantly reduces UCP3 gene expression. This result is consistent with our previous measurements indicating that, 2 h after a single capsiate administration in rat, UCP3 mRNA level was downregulated. 5 Actually, very few studies have investigated the effect of capsiate administration on UCP3 gene expression.
In an earlier study conducted in mice, it has been reported that a daily administration of capsiate (10 mg kg À1 body weight) during a 2-week period did not change UCP3 gene expression. 12 Several potential confounding factors such as species and the capsiate concentration could explain this discrepancy. We found that chronic capsiate treatment increased the PCr content at rest and during the stimulation period. These results are similar to those previously obtained throughout an acute capsiate ingestion and further illustrate that UCP3 expression is altered by capsiate administration. 5 Intramuscular PCr concentration takes part to the CK reaction that reversibly transfers a high-energy phosphate bond from ATP to creatine (ATP þ creatine2PCr þ ADP þ H þ ). Considering that ATP generation is mainly aerobic at rest and that is controlled by ADP through a feedback loop, the increased resting PCr content could be translated as a compensatory mechanism aiming at keeping [ADP] constant in the face of Chronic effects of capsiate administration B Faraut et al a decrease in pH i , while mitochondrial function would be unchanged. This interpretation can however be excluded because both [ADP] and pH i were not altered at rest by capsiate treatment. It could however be hypothesized that the increased PCr content at rest is caused by a downward shift of the relationship between the oxidative rate of ATP production and ADP. In other words, for a given ADP concentration, the corresponding rate of aerobic ATP production would be higher and PCr would be spared. This assumption is consistent with the time-dependent changes in phosphorylated compounds and pH i measured during the stimulation period. Indeed, the alkalosis observed from the middle of the exercise period in capsiate-treated animals suggests both a lower glycolytic and a higher aerobic contribution to ATP synthesis. In addition, given that the capsiate treatment did not alter the mechanical performance, we can Chronic effects of capsiate administration B Faraut et al discard any change in energy demand as an accounting factor of the increased PCr concentration. The similar ADP time courses in both groups suggest that the higher oxidative contribution in the capsiate group occurred despite a near normal ADP activation. These results clearly show a potential effect of capsiate on energy metabolism at rest and during exercise and are in line with the previous results we reported about oxidative metabolism and free fatty acid level after acute capsiate ingestion. 5 We found that both body weight gain and abdominal fat volume were reduced in the capsiate-treated animals. Interestingly, these changes were coupled to an increased food intake. These data strongly support an enhanced fatty acids oxidation resulting from the chronic capsiate administration, given that free fatty acids are a major fuel in resting and exercising skeletal muscle. 13 Furthermore, the decreased abdominal fat volume measured in vivo was associated with a UCP3 downregulation suggesting that UCP3 expression could be involved in body weight regulation. Experiments conducted in UCP3 knockout mice have actually not illustrated a major involvement of UCP3 in the regulation of whole-body energy metabolism. [14] [15] [16] These genetically modified mice did not show changes in body mass and their metabolic rates were similar to those measured in the wild-type animals. Alternatively, on the basis of the present results, we hypothesize that UCP3 is involved in the control of ATP production in skeletal muscle at rest and during muscle activity. The increased rate of oxidative ATP production reported in rat skeletal muscle at rest and during exercise and resulting from a reduced UCP3 expression 5 and the changes in muscle energetics associated with UCP3 overexpression in mice 17, 18 are in agreement with our assumption. Although the changes we reported at the whole-body level likely result from the capsiate-mediated UCP3 downregulation, one cannot rule out other effects of capsiate. For instance, it has been shown that a 2-week daily ingestion of purified capsiate in mice increases both oxygen consumption and epinephrine production. 9 The capsiate-mediated increase in catecholamine secretion could enhance energy metabolism and activate the hormone-sensitive lipase and the hydrolysis of white adipose tissue, an important energy store with a key role, more particularly in small animals, in the control of body weight. In addition, this 2-week capsiate ingestion protocol has been linked to an increased UCP1 gene expression, an increased fat oxidation at rest accounting for the increased energy turnover 12 and a reduced body fat accumulation. 9 On that basis, in addition to the downregulation of UCP3, a UCP1 overexpression might also be linked to the capsiate-mediated metabolic changes reported in the present study. Obesity results from an imbalance between energy intake and expenditure thereby leading to a significant weight gain and an excessive intra-abdominal adipose tissue accumulation. 19 We have shown in the present study that a chronic capsiate administration reduced abdominal fat volume as measured from MR images. The reliability of this quantitative method has been previously demonstrated in rats. 20 In humans, it has been reported that a significant muscle reduction of UCP3 mRNA expression was associated with a weight loss 21, 22 further illustrating the potential role of UCP3
in the control of weight gain. Interestingly, the capsiateadministrated rats showed a lower weight gain coupled to a decreased abdominal fat content although they were hyperphagic as compared to control animals. We have also clearly demonstrated that capsiate administration was directly or indirectly linked to a UCP3 downregulation. Regarding these results, one could hypothesize that change in UCP3 expression is a causative factor of weight loss. Overall, our results suggest that UCP3 expression might be directly or indirectly linked to the control of energy expenditure. Considering the presently reported effects of capsiate, this natural and edible compound could be worth considered as an attractive compound for the control of body weight. Chronic effects of capsiate administration B Faraut et al
